[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.145.124. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
August 2018

The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication

Author Affiliations
  • 1Department of Neurosciences, Katholieke Universiteit Leuven, Kortenberg, Belgium
  • 2University Psychiatric Centre, Katholieke Universiteit Leuven, Kortenberg, Belgium
JAMA Psychiatry. 2018;75(8):771-772. doi:10.1001/jamapsychiatry.2018.1080

Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.1-3 As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.

×